###begin article-title 0
###xml 88 93 88 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PARK2</italic>
Effective quantitative real-time polymerase chain reaction analysis of the parkin gene (PARK2) exon 1-12 dosage
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 61 67 61 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PARK2 </italic>
One of the causes of Parkinson's disease is mutations in the PARK2 gene. Deletions and duplications of single exons or exon groups account for a large proportion of the gene mutations. Direct detection of these mutations can be used for the diagnosis of Parkinson's disease.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 156 162 156 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PARK2 </italic>
To detect these mutations, we developed an effective technique based on the real-time TaqMan PCR system, which allows us to evaluate the copynumbers of the PARK2 gene exons by comparing the intensity of the amplification signals from some exon of this gene with that of the beta-globin gene (the internal control).
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 48 54 48 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PARK2 </italic>
###xml 65 73 <span type="species:ncbi:9606">patients</span>
###xml 164 172 <span type="species:ncbi:9606">patients</span>
We analyzed rearrangements in exons 1-12 of the PARK2 gene in 64 patients from Russia with early-onset Parkinson's disease. The frequency of these mutations in our patients was 14%.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 126 132 126 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PARK2 </italic>
###xml 179 186 <span type="species:ncbi:9606">patient</span>
We have developed a simple, accurate, and reproducible method applicable to the rapid detection of exon rearrangements in the PARK2 gene. It is suitable for the analysis of large patient groups, and it may become the basis for a diagnostic test.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 312 317 312 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PARK2</italic>
###xml 341 342 341 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 345 350 345 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PARK6</italic>
###xml 373 374 373 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 375 376 375 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 383 388 383 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PARK7</italic>
###xml 410 411 410 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
Parkinson's disease (PD) is one of the most common neurodegenerative disorders. It has a significant genetic component, particularly in individuals with early onset (younger than 50 years). To date, associations between three different genes/loci and early-onset Parkinson's disease (EOPD) have been identified: PARK2, which encodes parkin [1], PARK6, which encodes PINK1 [2,3], and PARK7, which encodes DJ-1 [4].
###end p 11
###begin p 12
###xml 219 220 219 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 387 393 387 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PARK2 </italic>
###xml 399 400 399 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 401 403 401 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 455 461 455 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PARK2 </italic>
###xml 592 593 592 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 594 595 594 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 596 598 596 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 618 624 618 624 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PARK2 </italic>
###xml 725 727 725 727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 728 730 728 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 938 940 938 940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 989 995 989 995 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PARK2 </italic>
###xml 1144 1146 1144 1146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1147 1149 1147 1149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1190 1196 1190 1196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PARK2 </italic>
###xml 1387 1388 1387 1388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1389 1390 1389 1390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1391 1393 1391 1393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1394 1396 1394 1396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 521 529 <span type="species:ncbi:9606">patients</span>
###xml 637 645 <span type="species:ncbi:9606">patients</span>
###xml 1226 1234 <span type="species:ncbi:9606">patients</span>
Parkin is expressed primarily in the nervous system and is one of the family of E3 ubiquitin ligases, which attach short ubiquitin peptide chains to proteins to tag them for degradation through the proteasomal pathway [5]. Different types of mutations, from point mutations to complex rearrangements, including deletions and multiplications of complete exons, have been described in the PARK2 gene [6-10]. Homozygous or compound heterozygous mutations in PARK2 are considered to cause the disease in approximately 50% of patients with the rare familial form, autosomal recessive juvenile PD [5,6,11]. The frequency of PARK2 mutations in patients with sporadic EOPD may depend on the inclusion criteria and ethnic background [12,13]. In general, parkin gene mutations are considered to be autosomal recessive. However, heterozygous mutations have been found to be associated with subclinical damage to dopamine metabolism in the striatum [14]. It is possible that heterozygous mutations in PARK2 can lead in some cases to early-onset or late-onset sporadic PD or to an increase in the risk of the disease, given interactions with other factors [15-17]. Therefore, it is necessary to analyze PARK2 mutations in a large group of patients with sporadic PD to test this hypothesis. One distinctive feature of the mutations in this gene is the high frequency (33%-67%) of exon rearrangements [7-9,18-20]. This type of mutation is only detectable by gene copy dosage assays. Here, we describe an effective and quantitative real-time polymerase chain reaction (PCR) method for the analysis of exon dosage in this gene.
###end p 12
###begin title 13
Methods
###end title 13
###begin title 14
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and samples
###end title 14
###begin p 15
###xml 456 458 454 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 679 681 677 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 697 703 695 701 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PARK2 </italic>
###xml 775 777 773 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 778 780 776 778 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 889 893 887 889 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 25 33 <span type="species:ncbi:9606">patients</span>
###xml 146 154 <span type="species:ncbi:9606">patients</span>
###xml 348 356 <span type="species:ncbi:9606">patients</span>
###xml 465 477 <span type="species:ncbi:9606">participants</span>
###xml 710 718 <span type="species:ncbi:9606">patients</span>
###xml 787 795 <span type="species:ncbi:9606">patients</span>
We studied two groups of patients: nine with autosomal recessive juvenile PD and 64 with apparent EOPD, with an age of onset of </= 50 years. All patients were examined clinically at the Institute of Neurology in the Russian Academy of Medical Sciences, Moscow. The diagnosis was confirmed using the UK Parkinson's Disease Brain Bank Criteria. All patients were assessed using a standard Unified Parkinson's Disease Rating Scale and Hoehn and Yahr scores [23]. All participants in this study gave their informed consent, and the study was approved by the local ethics committee. Venous whole blood was taken, and DNA was extracted from peripheral leukocytes by standard methods [24]. Deletions in PARK2 in the patients with juvenile PD were detected as described previously [10,17], and patients' DNA samples were used to optimize the efficiency of the real-time PCR method based on TaqMan(R) technology (Applied Biosystems, Foster City, CA, USA).
###end p 15
###begin title 16
Exon dosage analysis
###end title 16
###begin p 17
###xml 37 43 37 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PARK2 </italic>
###xml 131 137 131 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PARK2 </italic>
###xml 165 166 165 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 239 245 236 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PARK2 </italic>
###xml 359 361 353 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 370 371 364 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 519 520 512 513 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 583 589 576 582 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PARK2 </italic>
###xml 662 666 651 655 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq </italic>
###xml 765 771 754 760 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PARK2 </italic>
###xml 1045 1046 1013 1014 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 1688 1694 1652 1658 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PARK2 </italic>
###xml 1790 1796 1751 1757 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PARK2 </italic>
###xml 1837 1840 1795 1798 <sub xmlns:xlink="http://www.w3.org/1999/xlink">p/b</sub>
###xml 1919 1921 1873 1875 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
Primers and probes for exons 1-12 of PARK2 were designed using Vector NTI Suite 9 software (Invitrogen, Carlsbad, CA, USA) and the PARK2 sequence (GenBank: ) (Table 1). The beta-globin gene was coamplified with each individual exon of the PARK2 gene as the internal standard. Primers and probe sequences for the beta-globin gene were as described previously [25] (Table 1). PCR was performed in 25 muL reaction volumes containing 10-20 ng of genomic DNA, 1 x PCR buffer (Syntol Corporation, Moscow, Russia), 2.5 mM MgCl2, 10 pM of the appropriate primers for the individual exons of PARK2 and the beta-globin gene, 200 muM of each dNTP, 1.25 units of Hot-Rescue Taq DNA polymerase (Syntol Corporation, Moscow, Russia) and 4 pM of probes for the individual exons of PARK2 and the beta-globin gene, designed using TaqMan chemistry (Syntol Corporation, Moscow, Russia). Amplification was performed for 2 min at 50degreesC, 10 min at 95degreesC, and 40 cycles of 15 s at 95degreesC and 50 s at the appropriate annealing temperature (Tann; see Table 1). The fluorescence intensity of the PCR products was measured using an ANA-32 machine (Institute for Analytical Instrumentation, St. Petersburg, Russia). All samples were tested in triplicate. We used the value of the cycle threshold (CT) to perform our calculations. The ANA-32 machine software determined the CT for every well by second-degree calculation. This method of CT determination is user independent and is based on a second-derivative value of the real-time fluorescence intensity curve. Because three different measurements were obtained per sample, the average CT (DeltaCt) and standard deviation (SD) were calculated for both PARK2 and the beta-globin gene. The internal control allowed the calculation of the relative ratio of PARK2 to the beta-globin gene concentrations (Rp/b). This was calculated using DeltaCt according to the formula of Livak et al. [26]:
###end p 17
###begin p 18
Primers and probe sequences and annealing temperatures used.
###end p 18
###begin p 19
###xml 1 5 1 5 <sub xmlns:xlink="http://www.w3.org/1999/xlink">p/b </sub>
###xml 9 24 9 16 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-(&#916;&#916;Ct)</sup>
Rp/b = 2 -(DeltaDeltaCt)
###end p 19
###begin p 20
###xml 30 42 18 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-globin </italic>
###xml 69 75 50 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PARK2 </italic>
###xml 104 116 81 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-globin </italic>
###xml 143 149 113 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PARK2 </italic>
###xml 117 124 <span type="species:ncbi:9606">patient</span>
###xml 150 157 <span type="species:ncbi:9606">patient</span>
where DeltaDeltaCt = [DeltaCt beta-globin (control sample) - DeltaCt PARK2 (control sample)] - [DeltaCt beta-globin (patient sample) - DeltaCt PARK2 (patient sample)]. All positive results were confirmed at least twice, and the average ratio was calculated. All samples with homozygous or heterozygous exon rearrangements affecting only one exon were confirmed with an independent set of primers to avoid any false positive results caused by primer mismatch associated with undetected polymorphisms.
###end p 20
###begin title 21
Results
###end title 21
###begin p 22
###xml 101 107 101 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PARK2 </italic>
We performed relative quantitative real-time PCR amplification based on TaqMan technology to analyze PARK2 exon dosage. With this method, it is possible to analyze the deletions and duplications of exons 1-12.
###end p 22
###begin p 23
###xml 179 185 179 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PARK2 </italic>
###xml 238 240 238 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 69 77 <span type="species:ncbi:9606">patients</span>
###xml 122 130 <span type="species:ncbi:9606">patients</span>
Exon dosage analysis was performed for nine genomic DNA samples from patients with autosomal recessive juvenile PD. These patients have been described elsewhere, and heterozygous PARK2 exon deletions have been identified in some of them [17].
###end p 23
###begin p 24
###xml 22 28 22 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PARK2 </italic>
###xml 112 113 109 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 243 249 240 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PARK2 </italic>
The relative ratio of PARK2 to the beta-globin gene concentration was calculated for all DNA samples (see Table 2). Based on the observed variability in the values of the ratios in normal individuals and in positive controls with heterozygous PARK2 rearrangements, we considered ratios between 0.7 and 1.3 as normal. Values lower than 0.6 or higher than 1.4 were interpreted as heterozygous deletions or duplications of the assessed exon, respectively. In the case of homozygous deletions, the ratio was 0.3 or lower.
###end p 24
###begin p 25
###xml 74 82 <span type="species:ncbi:9606">patients</span>
Results of exon dosage analysis for the seventeen previously described PD patients and controls.
###end p 25
###begin p 26
###xml 96 102 96 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PARK2 </italic>
###xml 257 258 254 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 275 281 272 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PARK2 </italic>
###xml 572 573 569 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 23 31 <span type="species:ncbi:9606">patients</span>
###xml 236 244 <span type="species:ncbi:9606">patients</span>
###xml 307 315 <span type="species:ncbi:9606">patients</span>
###xml 317 325 <span type="species:ncbi:9606">patients</span>
###xml 376 384 <span type="species:ncbi:9606">patients</span>
###xml 468 475 <span type="species:ncbi:9606">patient</span>
###xml 487 494 <span type="species:ncbi:9606">patient</span>
###xml 527 535 <span type="species:ncbi:9606">patients</span>
###xml 537 545 <span type="species:ncbi:9606">patients</span>
###xml 843 851 <span type="species:ncbi:9606">patients</span>
We examined 64 Russian patients with EOPD for exon rearrangements. The majority showed relative PARK2 exon to the beta-globin gene ratios of approximately 0.8-1.2 for all exons under study. Alterations in gene dosage were found in nine patients (14%; Table 3). We detected a PARK2 exon 5 duplication in two patients (patients 8 and 9). Homozygous deletions were found in two: patients 2 (exon 4) and 5 (exon 3). Heterozygous deletion of a single exon was found in one patient (exon 3 in patient 6) and of several exons in four patients (patients 1, 3, 4, and 7; see Table 3). We could not distinguish heterozygous contiguous multiexonic deletions from compound heterozygous deletions. For precise genotype determination, it will be necessary to analyze additional intronic DNA markers or to study the parkin gene deletions in the relatives of patients.
###end p 26
###begin p 27
###xml 48 56 <span type="species:ncbi:9606">patients</span>
Results of exon dosage analysis for the nine PD patients with exon deletions and duplications.
###end p 27
###begin title 28
Discussion
###end title 28
###begin p 29
###xml 112 118 112 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PARK2 </italic>
###xml 195 201 195 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PARK2 </italic>
###xml 445 453 <span type="species:ncbi:9606">patients</span>
###xml 539 547 <span type="species:ncbi:9606">patients</span>
###xml 642 650 <span type="species:ncbi:9606">patients</span>
Here, we describe a cost-effective technique for the rapid and accurate detection of exon rearrangements in the PARK2 gene, using a real-time TaqMan PCR system. Joint amplification of individual PARK2 exons and the beta-globin gene as the internal control and the use of the least-squares method to calculate the cycle threshold ensured the adequacy of the analysis and the repeatability of the method. For method verification, we examined nine patients with juvenile autosomal recessive PD whose deletion status determined earlier (three patients without deletions and six with monoexonic heterozygous deletions). We also studied 64 Russian patients with EOPD and found exon rearrangements in nine of them using this method. Our method is suitable for the rapid detection and screening of exon rearrangements in the parkin gene. However, for heterozygous contiguous deletions of neighboring exons, it cannot distinguish between a large contiguous deletion on a single chromosome and a combination of two deletions on both chromosomes. This method is not applicable to the detection of point mutations or small sequence changes.
###end p 29
###begin p 30
###xml 71 77 71 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PARK2 </italic>
###xml 105 106 105 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 107 108 107 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 109 111 109 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 112 114 112 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 133 134 133 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 487 493 487 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PARK2 </italic>
###xml 629 630 629 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 631 633 631 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 634 636 634 636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 775 777 775 777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 876 882 876 882 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PARK2 </italic>
###xml 1133 1134 1130 1131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1135 1137 1132 1134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1138 1140 1135 1137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
To date, several studies have addressed the question of exon dosage in PARK2 using different approaches [7,8,20-22]. Lucking et al. [7] performed the first screening to determine the exon dosage based on semiquantitative multiplex PCR. However, the amounts of PCR products were measured in the putative log-linear phase of their multiplex PCR without consideration of the constant amplification efficiency of all primer pairs. Other previously described methods for the detection of the PARK2 gene exon dosage and the method described here are based on real-time PCR, which provides a precise measurement of the cycle threshold [8,20-22]. One such assay was based on an intercalating dye (SYBR Green I), which functions as a fluorescent reporter, and used unlabeled primers [20]. Because that method uses only a single fluorescent reporter, two independent amplifications (of PARK2 and the beta-globin gene) are necessary for each DNA sample. However, application of the LightCycler (Roche Applied Science, Indianapolis, IN, USA) or TaqMan system allows us to carry out only one multiplex amplification reaction for each DNA sample [8,21,22]. This improves sensitivity and repeatability and reduces the time taken. Here, we used a combination of ROX-labeled parkin gene and FAM-labeled beta-globin gene probes in a single-tube multiplex PCR amplification. To avoid problems of the possible loss of signal when there are variations within the binding sites, we selected probes with low melting temperatures. The annealing temperature we used was 60degreesC. In the case of a mismatch, such probes will still generate a signal.
###end p 30
###begin p 31
Both the TaqMan and the LightCycler systems allow the application of quantitative real-time PCR assays by using labeled oligonucleotide probes, which generate sequence-specific signals. In the TaqMan system, only one probe is used for each locus, whereas in the LightCycler system, two hybridization probes are necessary, so it is more complicated.
###end p 31
###begin p 32
###xml 71 73 71 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 74 76 74 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 96 98 96 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 272 274 272 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 275 277 275 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 278 280 278 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 281 283 281 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 403 405 403 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 620 622 617 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 254 262 <span type="species:ncbi:9606">patients</span>
###xml 447 452 <span type="species:ncbi:9606">human</span>
###xml 550 555 <span type="species:ncbi:9606">human</span>
Two other groups have measured exon dosage based on TaqMan technology [21,22]. Maruyama et al. [21] performed a PCR assay with TaqMan probes but only for exons 1-5. However, rearrangements in other exons (7-12) have been described in some populations of patients with PD [10,13,15,17]. Thus, the determination of those deletions and duplications is very important for diagnostic purposes. Sinha et al. [22] used an 84-bp fragment of a single-copy human beta-actin gene as the internal control. However, in that technique variant, a standard curve of human genomic DNA concentrations must be generated for every PCR run [22], so it is more complicated and less repeatable than our method.
###end p 32
###begin p 33
###xml 355 357 355 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
All these methods are based on different types of real-time PCR. Recently, a new approach has been described, called multiplex ligation-dependent probe amplification (MLPA). MLPA is based on the combination of a ligation reaction and standard PCR followed by electrophoresis. It has been shown that this method is also applicable to exon dosage analysis [27]. However, a direct relationship between exon dosage and the amount of the ligation reaction product has not yet been proved. Thus, MLPA can be considered only as a semiquantitative method and not as an alternative to real-time-PCR-based methods. In our opinion, it would be ideal to combine real-time TaqMan PCR and MLPA to confirm the results further.
###end p 33
###begin title 34
Conclusion
###end title 34
###begin p 35
###xml 118 124 118 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PARK2 </italic>
###xml 132 140 <span type="species:ncbi:9606">patients</span>
###xml 524 531 <span type="species:ncbi:9606">patient</span>
This TaqMan real-time PCR methodology can be applied to the rapid and precise screening of exon rearrangements in the PARK2 gene in patients with PD. It analyzes all relevant deletions and duplications of exons 1-12. The determination of the TaqMan-based cycle threshold is more precise than earlier methods based on SYBR Green I labeling. A very precise measurement of exon dosage is possible using a second-derivative value of the real-time fluorescence intensity curve. This method is applicable to the analysis of large patient groups and may become the basis for a diagnostic test.
###end p 35
###begin title 36
List of abbreviations
###end title 36
###begin p 37
PD: Parkinson's disease
###end p 37
###begin p 38
EOPD: early-onset Parkinson's disease
###end p 38
###begin p 39
PCR: polymerase chain reaction
###end p 39
###begin p 40
CT: cycle threshold
###end p 40
###begin p 41
SD: standard deviation
###end p 41
###begin title 42
Competing interests
###end title 42
###begin p 43
The author(s) declare that they have no competing interests.
###end p 43
###begin title 44
Authors' contributions
###end title 44
###begin p 45
MIS and EVS designed and executed all the experiments. MIS and EVS analyzed the data and wrote the paper. GHB, SNI and III-S participated in the acquisition of data and helped draft the manuscript. PAS and SAL were involved in study design and helped draft the manuscript. All authors read and approved the final manuscript.
###end p 45
###begin title 46
Pre-publication history
###end title 46
###begin p 47
The pre-publication history for this paper can be accessed here:
###end p 47
###begin p 48

###end p 48
###begin title 49
Acknowledgements
###end title 49
###begin p 50
This study was supported in part by a grants of the Russian Basic Research Foundation (Grant 06-04-49368-a, Grant 04-04-08117-a), Russian Academy of Sciences program "Molecular and Cellular Biology".
###end p 50
###begin article-title 51
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
###end article-title 51
###begin article-title 52
###xml 90 95 <span type="species:ncbi:9606">human</span>
Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome1p35-p36
###end article-title 52
###begin article-title 53
Hereditary early-onset Parkinson's disease caused by mutations in PINK1
###end article-title 53
###begin article-title 54
Mutation in DJ-1 gene associated with autosomal recessive early-onset parkinsonism
###end article-title 54
###begin article-title 55
Genetic contributions to Parkinson's disease
###end article-title 55
###begin article-title 56
A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe
###end article-title 56
###begin article-title 57
Association between early-onset Parkinson's disease and mutations in the Parkin gene
###end article-title 57
###begin article-title 58
The importance of gene dosage studies: mutational analysis of the parkin gene in early onset parkinsonism
###end article-title 58
###begin article-title 59
Evaluation of 50 probands with early-onset Parkinson's disease for Parkin mutations
###end article-title 59
###begin article-title 60
Mutation analysis of the parkin gene in Russian families with autosomal recessive juvenile parkinsonism
###end article-title 60
###begin article-title 61
Complex relationship between parkin mutations and Parkinson disease
###end article-title 61
###begin article-title 62
###xml 142 150 <span type="species:ncbi:9606">patients</span>
Detection of Parkin (PARK2) and DJ1 (PARK7) mutations in early-onset Parkinson disease: Parkin mutation frequency depends on ethnic origin of patients
###end article-title 62
###begin article-title 63
###xml 35 43 <span type="species:ncbi:9606">patients</span>
Novel parkin mutations detected in patients with early-onset Parkinson's disease
###end article-title 63
###begin article-title 64
Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the parkin gene
###end article-title 64
###begin article-title 65
Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease
###end article-title 65
###begin article-title 66
Parkin mutations and susceptibility alleles in late-onset Parkinson's disease
###end article-title 66
###begin article-title 67
Analysis of deletion mutations in the PARK2 gene in idiopathic Parkinson's disease
###end article-title 67
###begin article-title 68
New parkin mutations and atypical phenotypes in families with autosomal recessive parkinsonism
###end article-title 68
###begin article-title 69
###xml 33 41 <span type="species:ncbi:9606">patients</span>
Parkin mutations are frequent in patients with isolated early-onset parkinsonism
###end article-title 69
###begin article-title 70
###xml 35 43 <span type="species:ncbi:9606">patients</span>
Novel parkin mutations detected in patients with early-onset parkinson's disease
###end article-title 70
###begin article-title 71
###xml 79 87 <span type="species:ncbi:9606">patients</span>
Novel mutations, pseudo-dominant inheritance, and possible familial affects in patients with autosomal recessive juvenile parkinsonism
###end article-title 71
###begin article-title 72
Prevalence of parkin gene mutations and variations in idiopathic Parkinson's disease
###end article-title 72
###begin article-title 73
Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases
###end article-title 73
###begin article-title 74
###xml 55 60 <span type="species:ncbi:9606">human</span>
A simple salting out procedure for extracting DNA from human nucleated cells
###end article-title 74
###begin article-title 75
Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis
###end article-title 75
###begin article-title 76
Comparative Ct method. ABI Prism 7700 Sequence Detection System
###end article-title 76
###begin article-title 77
Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification
###end article-title 77

